Both Europe and Japan have rejected the US's continuations approach
I came across a very interesting perspective on the US claims and continuations debate posted on Holman’s Biotech IP Blog. Basically, it seems to be saying that the JPO and the EPO have had cause to look at claims and continuations in recent years,…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.